Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics
Launched by THE FIRST AFFILIATED HOSPITAL OF NANCHANG UNIVERSITY · Jan 20, 2024
Trial Information
Current as of July 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to better understand severe acute pancreatitis, a serious condition where the pancreas becomes inflamed. Researchers will study samples from 30 healthy individuals and 146 patients with varying degrees of pancreatitis—mild, moderate, and severe. The main goal is to explore how changes in gut bacteria and blood composition relate to the severity of the disease. This could help identify early warning signs and biomarkers, which are substances that can indicate the presence or severity of a disease.
To participate, patients should be between 18 and 75 years old and must have experienced acute pancreatitis within the last 72 hours. Healthy volunteers should also be in the same age range but must not have had any history of acute pancreatitis and should be in good health based on routine lab tests. Participants will provide blood and stool samples, and while the study is not currently recruiting, it aims to gather important information that could improve future treatments for acute pancreatitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients group:
- • ① Age between 18 and 75 years old;
- • ② Within 72 hours of AP onset;
- • ③ AP patients who meet the 2012 Atlanta AP Classification and Diagnostic Criteria.
- Healthy control group:
- • Age between 18 and 75 years old; ② No history of acute pancreatitis; ③ Routine laboratory tests such as blood routine and fecal routine are normal.
- Exclusion Criteria:
- • Used antibiotics, probiotics, and acid suppressants 4 weeks before enrollment;
- • Pregnant and lactating women;
- • Hypothyroidism, nephrotic syndrome, Cushing's syndrome, AIDS;
- • Chronic pancreatitis, pancreatic cancer; ⑤ Severe history of cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; ⑥ Unsigned informed consent form.
About The First Affiliated Hospital Of Nanchang University
The First Affiliated Hospital of Nanchang University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and high-quality patient care. As a prominent teaching hospital, it plays a pivotal role in medical education and training, fostering a collaborative environment for healthcare professionals. With a commitment to excellence, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes and enhancing patient safety. Its state-of-the-art facilities and multidisciplinary expertise position it as a key player in the advancement of medical science and the development of new therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanchang, Jiangxi, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported